搜索结果

Search Results for " bet bd2-in-1 "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T79527	BET BD2-IN-1	Epigenetic Reader Domain	Chromatin/Epigenetic
	BET BD2-IN-1（compound 45）为BETBD2选择性抑制剂，IC50值为1.6 nM，通过抑制STAT3与NF-κB活性，阻断Th17细胞的分化，适用于银屑病与炎症性肠病研究。
T9619	I-BET567
	I-BET567 是一种有效、具有口服活性的泛BET 候选抑制剂，对 BRD4 BD1 和 BD2 的pIC50s 分别为 6.9 和 7.2。I-BET567 在肿瘤和炎症的小鼠模型中已被证明有效。
T10773	CF53	Epigenetic Reader Domain; CDK	Cell Cycle/Checkpoint; Chromatin/Epigenetic
	CF53 是一种高效、选择性、可口服的 BET 抑制剂，对 BRD4 BD1 的 Ki 值为 <1 nM，Kd 值为 2.2 nM，IC50 值为 2 nM；CF53 对 BRD2，BRD3，BRD4 和 BRDT BET 蛋白的 BD1 和 BD2 两个结构域都有高亲和性，对其选择性远高于非含溴结构域 BET 蛋白。CF53 在体外和体内都具有显著的抗肿瘤活性。
T79610	BET-IN-17	Epigenetic Reader Domain	Chromatin/Epigenetic
	BET-IN-17（化合物16）作为BET家族的泛抑制剂，具有针对BETBD1和BETBD2的pIC50值，分别为7.8与7.6。
T39634	GSK097
	GSK097 is a highly potent and selective inhibitor of the second bromodomain (BD2) found in bromodomain and extra-terminal domain (BET) proteins. It exhibits a remarkable 2000-fold selectivity for BD2 over BD1, as indicated by BRD4 data. Additionally, GSK097 demonstrates solubility of over 1 mg/mL in FaSSIF media.
T79167	BET-IN-15	Epigenetic Reader Domain	Chromatin/Epigenetic
	BET-IN-15（化合物1）为一种有效的口服活性BET抑制剂，其对BRD4-BD1及BRD4-BD2的IC50分别为0.64 nM和0.25 nM，具有明显的抗增殖活性。
T79018	GSK217	Epigenetic Reader Domain	Chromatin/Epigenetic
	GSK217为一种针对(BET)第二溴化结构域(BD2)的强效、选择性及高溶解度抑制剂，应用于肿瘤及免疫炎症研究领域。
T63418	GSK040
	GSK040 是一种有效和具有选择性的BETBD2抑制剂，pIC50值为 8.3。GSK040 对 BETBD2的选择性比 BETBD1(pIC50=4.6) 高 5000 倍。GSK040 可用于肿瘤学和免疫学疾病的研究。
T36103	TW9 TW9
	TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1It is selective for BD2 over BD1 in BRD4 (IC50= 0.72 μM) and for HDAC1 over HDAC2 (IC50= 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistica...
T36574	GW841819X GW841819X
	GW841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomains. GW841819X was a single enantiomer but of undefined chirality at the 4-position of the benzodiazepine ring3. GW841819X and JQ1 were recently discovered that bind to the acetyl-lysine binding pocket of BET bromodomains with Kd ranges from 50 to 370 nM [1]. GW841819X bounded to both the individual BD1 and BD2 domains with affinities of 46 and 52.5 nM, respectively. GW841819X-Brd3 interaction was estimated to be around 70...